Takeda forms immuno-oncology partnership with Shattuck Labs

Takeda has announced a new research collaboration with Shattuck Labs that aims to develop immunotherapy treatments for cancer.

The companies will  explore and develop checkpoint fusion proteins with the potential to become highly differentiated next-generation immunotherapies, with Takeda to receive options for exclusive global development and commercialisation rights for up to four molecules resulting from the collaboration.

Shattuck Labs will utilise its Agonist Redirected Checkpoint (ARC) platform to aid this research. The platform combines two binding domains to create fusion proteins that potentially restore and enhance immune system function in a single construct.

The partnership includes two preclinical and four discovery-stage programmes, with Takeda to provide funding for preclinical and clinical development, in exchange for an option to take an exclusive licence to further develop and commercialise up to four ARC molecules.

Dr Christopher Arendt, head of oncology and immunology at Takeda, said: "Research partnerships are a key aspect of our continued dedication to oncology innovation, and this collaboration will bring us closer to our goal of discovering, developing and delivering breakthrough oncology therapies."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.